• FirefoxInstall the new Firefox »
  •  Dow Down0.45% Nasdaq Down0.49%

    Curis, Inc. (CRIS)

    3.08 Down 0.07(2.22%) Feb 27, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Curis, Inc.
    4 Maguire Road
    Lexington, MA 02421
    United States - Map
    Phone: 617-503-6500
    Fax: 617-503-6501
    Website: http://www.curis.com

    Index Membership:N/A
    Full Time Employees:33

    Business Summary 

    Curis, Inc. is engaged in the research, development, and commercialization of cancer therapeutics. It focuses on developing cancer drug candidates, including CUDC-907, an oral, small molecule drug candidate that is designed to inhibit histone deacetylase and phosphatidylinositol-3-kinase, or PI3K enzymes; CUDC-427, an oral, small molecule drug candidate, which is designed to promote cancer cell death by antagonizing inhibitor of apoptosis proteins; Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor; and Debio 0932, a small molecule inhibitor of heat shock protein 90. It has collaborations with Genentech, Inc. and F. Hoffmann-La Roche Ltd. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Curis, Inc.

    Corporate Governance 
    Curis, Inc.’s ISS Governance QuickScore as of Jul 1, 2014 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Ali Fattaey Ph.D., 50
    Chief Exec. Officer, Pres and Director
    Mr. Daniel R. Passeri MSc., J.D., 54
    Vice Chairman and Strategic Advisor
    Mr. Michael P. Gray , 44
    Chief Financial Officer, Principal Accounting Officer, Chief Bus. Officer and Sec.
    Mr. Mark W. Noel , 56
    VP of Technology Management & Intellectual Property
    Dr. Jaye Viner M.D., MPH, 58
    Chief Medical Officer and Exec. VP
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders